By classifying Epipen as a generic product rather than a branded one, Mylan NV may have underpaid its Medicaid rebate by as much as $1.27 billion over the past decade, according to an estimate from the Health and Human Services Office of Inspector General (OIG). Read More
On the eve of the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Deciphera Pharmaceuticals LLC disclosed a $52 million series C financing to advance lead candidates DCC-2618 and DCC-3014 beyond phase I. Read More
Early cancer detection company Grail Inc. will merge with Hong Kong-based competitor Cirina Ltd. in an effort to boost its scientific efforts, as well as to better serve Asian markets. Financial details were undisclosed. Read More
Ohio Attorney General Mike DeWine filed a lawsuit Wednesday against Allergan plc, Endo Health Solutions Inc., Purdue Pharma LP, Johnson & Johnson and its subsidiary Janssen Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd. and its subsidiary Cephalon, alleging that they violated the Ohio Consumer Sales Practices Act and created a public nuisance by disseminating false and misleading statements about the risks and benefits of their opioid painkillers. Read More
Oncobiologics Inc., of Cranbury, N.J., said it completed the sale of notes and warrants under its amended notes and warrant purchase agreement, dated Dec. 22, 2016, and amended April 13, 2017. Read More
Biomarin Pharmaceutical Inc., of San Rafael, Calif., said the European Commission (EC) granted marketing authorization for Brineura (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 deficiency. Read More
Origin Inc., of Princeton, N.J., said the first 52 patients have been randomized in the phase IIb GENESIS trial, passing the halfway enrollment point. Read More
